# US 2012/0231467 A1 · Aptamers for C. Difficile Diagnostics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0231467 A1
- Document ID: US20120231467A1
- Status: Published application
- Kind: A1
- Application number: 13/417,035
- Filed: 2012-03-09
- Published: 2012-09-13
- Earliest claimed: 2011-03-10
- Assignees: SomaLogic, Inc.
- Inventors: Urs Ochsner; Evaldas Katilius; Nebojsa Janjic
- Web page: https://patentgrep.com/patent/US20120231467A1

## CPC

- G01N 33/573: for enzymes or isoenzymes
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12N 2310/16: Aptamers
- G01N 2333/91102: with definite EC number (2.4.1.-)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure relates generally to the field of nucleic acids and, more particularly, to aptamers capable of binding to toxins produced by Clostridium difficile; diagnostic kits and methods comprising such aptamers; and methods of making and using such aptamers.

## Claims

### Claim 1

An aptamer that binds to a toxin produced by C. difficile wherein said toxin is selected from toxin A, toxin B, binary toxin A chain, and binary toxin B chain.

### Claim 2 (depends on 1)

The aptamer of claim 1, comprising at least one pyrimidine modified at a C-5 position.

### Claim 3 (depends on 2)

The aptamer of claim 2, wherein said at least one pyrimidine modified at a C-5 position comprises a C-5 modification independently chosen from at least one of the modifications shown in FIG. 9.

### Claim 4 (depends on 2)

The aptamer of claim 2, wherein said at least one pyrimidine modified at a C-5 position comprises a C-5 modification independently chosen from benzylcarboxyamide, naphthylmethylcarboxyamide, tryptaminocarboxyamide, tyrosylcarboxyamide, 2-naphthylmethylcarboxyamide and phenethyl-1-carboxyamide.

### Claim 5 (depends on 2)

The aptamer of claim 2, wherein said aptamer further comprises at least one additional chemical modification, wherein said at least one additional chemical modification is a chemical substitution at one or more positions independently selected from the group consisting of a ribose position, a deoxyribose position, a phosphate position, and a base position.

### Claim 6 (depends on 5)

The aptamer of claim 5, wherein said at least one additional chemical modification is independently selected from the group consisting of a 2′-position sugar modification, a 2′-amino (2′-NH2), a 2′-fluoro (2′-F), a 2′-O-methyl (2′-OMe) a modification at a cytosine exocyclic amine, a substitution of 5-bromouracil, a substitution of 5-bromodeoxyuridine, a substitution of 5-bromodeoxycytidine, a backbone modification, methylation, a 3′ cap, and a 5′ cap.

### Claim 7 (depends on 4)

The aptamer of claim 4, wherein the aptamer binds to C. difficile toxin A.

### Claim 8 (depends on 4)

The aptamer of claim 4, wherein the aptamer binds to C. difficile toxin B.

### Claim 9 (depends on 4)

The aptamer of claim 4, wherein the aptamer binds to C. difficile binary toxin A chain.

### Claim 10 (depends on 4)

The aptamer of claim 4, wherein the aptamer binds to C. difficile binary toxin B chain.

### Claim at position 11

11-39. (canceled)

### Claim 40 (depends on 7)

The aptamer of claim 7 comprising a sequence selected from the group consisting of SEQ ID NOS: 1-4, 6-10, 12-14, 16-22, 24-27, or 29-31.

### Claim 41 (depends on 8)

The aptamer of claim 8 comprising a sequence selected from the group consisting of SEQ ID NOS: 33-46, 48-65, 67-74, 76-82, 84-89, 91-94, 96-97, or 99-108.

### Claim 42 (depends on 9)

The aptamer of claim 9 comprising a sequence selected from the group consisting of SEQ ID NOS: 109, 111-123, 126-133, 135-138, 140-144, or 146-150.

### Claim 43 (depends on 10)

The aptamer of claim 10 comprising a sequence selected from the group consisting of SEQ ID NOS: 153-156, 158-162.

### Claim at position 16

44-67. (canceled)

### Claim 68 (depends on 7)

The aptamer of claim 7 comprising a sequence selected from the group consisting of SEQ ID NOS: 5, 11, 15, 23 and 28.

### Claim at position 18

69-70. (canceled)

### Claim 71 (depends on 8)

The aptamer of claim 8 comprising a sequence selected from the group consisting of SEQ ID NOS: 32, 47, 66, 75, 83, 90, 95, and 98.

### Claim at position 20

72-73. (canceled)

### Claim 74 (depends on 9)

The aptamer of claim 9 comprising a sequence selected from the group consisting of SEQ ID NOS: 110, 124-125, 134, 139, and 145.

### Claim at position 22

75-76. (canceled)

### Claim 77 (depends on 10)

The aptamer of claim 10 comprising a sequence selected from the group consisting of SEQ ID NOS: 151-152 and 157.

### Claim at position 24

78-85. (canceled)

### Claim 86 (depends on 7)

The aptamer of claim 7, wherein said aptamer comprises a Kd for C. difficile toxin A of 30 nM or less.

### Claim 87 (depends on 8)

The aptamer of claim 8, wherein said aptamer comprises a Kd for C. difficile toxin B of 30 nM or less.

### Claim 88 (depends on 9)

The aptamer of claim 9, wherein said aptamer comprises a Kd for C. difficile binary toxin A chain of 30 nM or less.

### Claim 89 (depends on 10)

The aptamer of claim 10, wherein said aptamer comprises a Kd for C. difficile binary toxin B chain of 30 nM or less.

### Claim 90 (depends on 4)

The aptamer of claim 4, wherein said aptamer is nuclease resistant.

### Claim 91 (depends on 4)

The aptamer of claim 4, wherein said aptamer has a slow off rate.

### Claim 92 (depends on 4)

A method of detecting the presence of a C. difficile toxin in a test sample comprising contacting said test sample with the aptamer of claim 4.
